The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

Scientists say the drug stops the virus from replicating inside cells. The landmark deal to provide cheaper antiretroviral ...

Indian drugmakers Dr Reddy's Laboratories and Hetero Labs said on Wednesday that they will sell generic versions of a new and ...

Gilead's groundbreaking HIV prevention drug will soon be available at a fraction of its U.S. price in over 100 countries, ...

Year's supply of injectable to cost Rs 3,549, compared to over Rs 17 lakh in US. Powerful alternative to daily oral PrEP, ...

In his first term, President Trump pledged to boost HIV spending, with the lofty goal of bringing the epidemic to heel by ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Cork and Kerry share one HIV clinic, which is 'stretched', Cork Sexual Health Centre's fast-track cities programme manager ...

Lenacapavir is a long-acting HIV medication known as a capsid inhibitor. It works by blocking the virus's protective shell, ...

From 2027, Indian generics companies and Hetero Labs Dr. Reddy's will supply lenacapavir, a twice-yearly injectable PrEP with ~96-100% efficacy, for US$40 (R698) per person per year across 120 low- ...

Stigma and lack of support hinder PrEP use among Black women; clinician bias and discrimination worsen disparities.

This scenario of opaque pricing, restrictive licensing and inadequate global targets will leave far too many people at continued risk of preventable HIV ...